{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:49:53Z","timestamp":1790423393328,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"am","delay-in-days":257,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009012","name":"VASDHS","doi-asserted-by":"publisher","award":["I01BX003759"],"award-info":[{"award-number":["I01BX003759"]}],"id":[{"id":"10.13039\/100009012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00DA048970"],"award-info":[{"award-number":["R00DA048970"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA036612"],"award-info":[{"award-number":["R01DA036612"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R33DA038019"],"award-info":[{"award-number":["R33DA038019"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.neuropharm.2023.109544","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T11:05:46Z","timestamp":1681211146000},"page":"109544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Neurotensin receptor 1-biased ligand attenuates neurotensin-mediated excitation of ventral tegmental area dopamine neurons and dopamine release in the nucleus accumbens"],"prefix":"10.1016","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-7115","authenticated-orcid":false,"given":"Sarthak M.","family":"Singhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Zell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8572-6542","authenticated-orcid":false,"given":"Lauren","family":"Faget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Slosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-2141","authenticated-orcid":false,"given":"Lawrence S.","family":"Barak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony B.","family":"Pinkerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6176-8513","authenticated-orcid":false,"given":"Thomas S.","family":"Hnasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109544_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/(SICI)1096-9861(19981228)402:4<475::AID-CNE4>3.0.CO;2-9","article-title":"Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor","volume":"402","author":"Alexander","year":"1998","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib2","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1021\/acschembio.6b00291","article-title":"ML314: a biased neurotensin receptor ligand for methamphetamine abuse","volume":"11","author":"Barak","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109544_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.03.046","article-title":"The signaling signature of the neurotensin type 1 receptor with endogenous ligands","volume":"805","author":"Besserer-Offroy","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0169-328X(96)00289-6","article-title":"Chronic cocaine increases neurotensin gene expression in the shell of the nucleus accumbens and in discrete regions of the striatum","volume":"44","author":"Betancur","year":"1997","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109544_bib6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0031-6997(24)01509-6","article-title":"Neurotensin and dopamine interactions","volume":"53","author":"Binder","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109544_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/(SICI)1096-9861(19960909)373:1<76::AID-CNE7>3.0.CO;2-A","article-title":"Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor","volume":"373","author":"Boudin","year":"1996","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fendo.2013.00036","article-title":"Diverse roles of neurotensin agonists in the central nervous system","volume":"4","author":"Boules","year":"2013","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/bs4020125","article-title":"Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders","volume":"4","author":"Boules","year":"2014","journal-title":"Behav. Sci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib10","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/febs.15496","article-title":"Roles of dopamine and glutamate co-release in the nucleus accumbens in mediating the actions of drugs of abuse","volume":"288","author":"Buck","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2023.109544_bib11","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.peptides.2006.04.024","article-title":"Neurotensin: role in psychiatric and neurological diseases","volume":"27","author":"C\u00e1ceda","year":"2006","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.neuropharm.2023.109544_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2008.12.002","article-title":"Getting specialized: presynaptic and postsynaptic dopamine D2 receptors","volume":"9","author":"de Mei","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-8993(89)90723-3","article-title":"Autoradiographic localization of mu-opioid and neurotensin receptors within the mesolimbic dopamine system","volume":"488","author":"Dilts","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109544_bib14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3389\/fnins.2015.00404","article-title":"Glutamatergic transmission in drug reward: implications for drug addiction","volume":"9","author":"D'Souza","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2202-10-96","article-title":"Presynaptic action of neurotensin on dopamine release through inhibition of D(2) receptor function","volume":"10","author":"Fawaz","year":"2009","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/0269881115622240","article-title":"Neurotensin: a role in substance use disorder?","volume":"30","author":"Ferraro","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.brainresrev.2007.03.006","article-title":"Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides","volume":"55","author":"Ferraro","year":"2007","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2023.109544_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.brainresrev.2007.11.001","article-title":"Neurotensin receptors as modulators of glutamatergic transmission","volume":"58","author":"Ferraro","year":"2008","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2023.109544_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2014.01.025","article-title":"The role of D2-autoreceptors in regulating dopamine neuron activity and transmission","volume":"282","author":"Ford","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109544_bib20","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.peptides.2006.03.037","article-title":"Brain neurotensin, psychostimulants, and stress--emphasis on neuroanatomical substrates","volume":"27","author":"Geisler","year":"2006","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.neuropharm.2023.109544_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.conb.2011.09.009","article-title":"Integrating synaptic plasticity and striatal circuit function in addiction","volume":"22","author":"Grueter","year":"2012","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40263-021-00796-y","article-title":"Targeting \u03b2-arrestins in the treatment of psychiatric and neurological disorders","volume":"35","author":"Harris","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2023.109544_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam5402","article-title":"\u03b2-Arrestin-biased \u03b2-adrenergic signaling promotes extinction learning of cocaine reward memory","volume":"11","author":"Huang","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neuropharm.2023.109544_bib24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41586-020-1953-1","article-title":"Structure of the neurotensin receptor 1 in complex with \u03b2-arrestin 1","volume":"579","author":"Huang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109544_bib25","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1111\/j.1460-9568.2006.05151.x","article-title":"Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons","volume":"24","author":"Jomphe","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0306-4522(84)90203-3","article-title":"Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing","volume":"11","author":"Kalivas","year":"1984","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109544_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jphs.2021.05.013","article-title":"Diverse intracellular signaling pathways mediate the effects of neurotensin on the excitability of type II neurons in the rat dorsolateral bed nucleus of the stria terminalis","volume":"147","author":"Kaneko","year":"2021","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0306-4522(01)00614-5","article-title":"Presynaptic action of neurotensin on cultured ventral tegmental area dopaminergic neurones","volume":"111","author":"Legault","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109544_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108714","article-title":"Ionic and signaling mechanisms involved in neurotensin-mediated excitation of central amygdala neurons","volume":"196","author":"Lei","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109544_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-neuro-070815-013920","article-title":"The emergence of a circuit model for addiction","volume":"39","author":"L\u00fcscher","year":"2016","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/294587a0","article-title":"Neurotensin receptors are located on dopamine-containing neurones in rat midbrain","volume":"294","author":"Palacios","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109544_bib32","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1210\/en.2014-1986","article-title":"Ventral tegmental area neurotensin signaling links the lateral hypothalamus to locomotor activity and striatal dopamine efflux in male mice","volume":"156","author":"Patterson","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2023.109544_bib33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/jpet.300.1.305","article-title":"The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin","volume":"300","author":"Pettibone","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109544_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/syn.10049","article-title":"Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release","volume":"44","author":"Phillips","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2023.109544_bib35","doi-asserted-by":"crossref","first-page":"11144","DOI":"10.1523\/JNEUROSCI.3816-14.2015","article-title":"Neurotensin induces presynaptic depression of D2 dopamine autoreceptor-mediated neurotransmission in midbrain dopaminergic neurons","volume":"35","author":"Piccart","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/cne.1198","article-title":"High-affinity neurotensin receptors in the rat nucleus accumbens: subcellular targeting and relation to endogenous ligand","volume":"435","author":"Pickel","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib37","doi-asserted-by":"crossref","first-page":"8357","DOI":"10.1021\/acs.jmedchem.9b00340","article-title":"Discovery of \u03b2-arrestin biased, orally bioavailable, and CNS penetrant neurotensin receptor 1 (NTR1) allosteric modulators","volume":"62","author":"Pinkerton","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109544_bib38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/jpet.117.240622","article-title":"Arresting the development of addiction: the role of \u03b2-arrestin 2 in drug abuse","volume":"361","author":"Porter-Stransky","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109544_bib39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0006-8993(85)91542-2","article-title":"Comparative localization of neurotensin receptors on nigrostriatal and mesolimbic dopaminergic terminals","volume":"327","author":"Quirion","year":"1985","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109544_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.pharmtox.010909.105800","article-title":"Molecular mechanism of \u03b2-arrestin-biased agonism at seven-transmembrane receptors","volume":"52","author":"Reiter","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0006-8993(02)03271-7","article-title":"Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia","volume":"953","author":"Remaury","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109544_bib42","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/BF00967292","article-title":"Regional effects of neurotensin on the electrically stimulated release of [3H]dopamine and [14C]acetylcholine in the rat nucleus accumbens","volume":"17","author":"Reyneke","year":"1992","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2023.109544_bib43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0024-3205(03)00388-6","article-title":"Neurotensin agonists: possible drugs for treatment of psychostimulant abuse","volume":"73","author":"Richelson","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/(SICI)1096-9861(19980511)394:3<344::AID-CNE6>3.0.CO;2-1","article-title":"Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain","volume":"394","author":"Sarret","year":"1998","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib45","first-page":"253","article-title":"Autoradiographic evidence for the localization of high affinity neurotensin binding sites on dopaminergic nerve terminals in the nigrostriatal and mesolimbic pathways in rat brain","volume":"2","author":"Schotte","year":"1989","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2023.109544_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2019.05.001","article-title":"Mapping the populations of neurotensin neurons in the male mouse brain","volume":"76","author":"Schroeder","year":"2019","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2023.109544_bib47","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1124\/pr.116.012484","article-title":"The nucleus accumbens: mechanisms of addiction across drug classes reflect the importance of glutamate homeostasis","volume":"68","author":"Scofield","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109544_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180710","article-title":"Systemic PD149163, a neurotensin receptor 1 agonist, decreases methamphetamine self-administration in DBA\/2J mice without causing excessive sedation","volume":"12","author":"Sharpe","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109544_bib49","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1523\/JNEUROSCI.12-06-02433.1992","article-title":"Roles of intracellular cAMP and protein kinase A in the actions of dopamine and neurotensin on midbrain dopamine neurons","volume":"12","author":"Shi","year":"1992","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib50","doi-asserted-by":"crossref","first-page":"11166","DOI":"10.1523\/JNEUROSCI.0596-17.2017","article-title":"Distinctive modulation of dopamine release in the nucleus accumbens shell mediated by dopamine and acetylcholine receptors","volume":"37","author":"Shin","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib51","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.cell.2020.04.053","article-title":"\u03b2-Arrestin-Biased allosteric modulator of NTSR1 selectively attenuates addictive behaviors","volume":"181","author":"Slosky","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2023.109544_bib52","doi-asserted-by":"crossref","first-page":"8969","DOI":"10.1074\/jbc.R115.713313","article-title":"The \u03b2-arrestins: multifunctional regulators of G protein-coupled receptors","volume":"291","author":"Smith","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2023.109544_bib53","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/0306-4522(94)90295-X","article-title":"SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission","volume":"59","author":"Steinberg","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109544_bib54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1139\/jpn.0627","article-title":"The role of neurotensin in central nervous system pathophysiology: what is the evidence?","volume":"31","author":"St-Gelais","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib55","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1523\/JNEUROSCI.5376-03.2004","article-title":"Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons","volume":"24","author":"St-Gelais","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib56","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1152\/jn.00279.2015","article-title":"Neurotensin inhibits both dopamine- and GABA-mediated inhibition of ventral tegmental area dopamine neurons","volume":"114","author":"Stuhrman","year":"2015","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2023.109544_bib57","doi-asserted-by":"crossref","first-page":"9174","DOI":"10.1074\/jbc.M110.166454","article-title":"Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism","volume":"286","author":"Thibault","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2023.109544_bib58","doi-asserted-by":"crossref","DOI":"10.3791\/53825","article-title":"Preparation of acute brain slices using an optimized N-Methyl-D-glucamine protective recovery method","author":"Ting","year":"2018","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.neuropharm.2023.109544_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108005","article-title":"Neurotensin in reward processes","volume":"167","author":"Torruella-Su\u00e1rez","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109544_bib60","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/ejn.13858","article-title":"Diverse actions of the modulatory peptide neurotensin on central synaptic transmission","volume":"49","author":"Tschumi","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib61","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.1523\/JNEUROSCI.1395-20.2022","article-title":"Neurotensin release from dopamine neurons drives long-term depression of substantia nigra dopamine signaling","volume":"42","author":"Tschumi","year":"2022","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109544_bib62","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1471-4159.1991.tb02578.x","article-title":"Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism","volume":"56","author":"von Euler","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2023.109544_bib63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0306-4522(99)00449-2","article-title":"Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area","volume":"95","author":"Werkman","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109544_bib64","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molmed.2010.11.004","article-title":"Therapeutic potential of \u03b2-arrestin- and G protein-biased agonists","volume":"17","author":"Whalen","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.neuropharm.2023.109544_bib65","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.celrep.2017.08.001","article-title":"Neurotensin receptor-1 identifies a subset of ventral tegmental dopamine neurons that coordinates energy balance","volume":"20","author":"Woodworth","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2023.109544_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.npep.2018.02.003","article-title":"Determination of neurotensin projections to the ventral tegmental area in mice","volume":"68","author":"Woodworth","year":"2018","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2023.109544_bib67","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0191-17.2018","article-title":"Identification of neurotensin receptor expressing cells in the ventral tegmental area across the lifespan","volume":"5","author":"Woodworth","year":"2018","journal-title":"eNeuro"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082300134X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082300134X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:22:57Z","timestamp":1758439377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082300134X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":67,"alternative-id":["S002839082300134X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109544","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurotensin receptor 1-biased ligand attenuates neurotensin-mediated excitation of ventral tegmental area dopamine neurons and dopamine release in the nucleus accumbens","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109544"}}